Kestra Medical Technologies, Ltd. (KMTS) reported its first‑quarter results for the period ended July 31, 2026, showing a wider net loss despite a 60% increase in revenue, and announced an upward revision of its full‑year 2027 outlook.
Kestra Medical specializes in cardiovascular disease, offering connected monitoring, therapeutic interventions, and data‑driven clinical insights. Its flagship Cardiac Recovery System is an integrated platform aimed at patients at heightened risk of sudden cardiac arrest during recovery.
The first‑quarter net loss widened to $44.09 million, or $0.75 per share, compared with $25.83 million, or $0.50 per share, in the prior year.
Revenue increased to $30.97 million, up from $19.37 million a year earlier, driven by growth in the wearable cardioverter defibrillator market, competitive gains, and expansion into new sales territories.
The broader loss was accompanied by a rise in operating loss to $37.66 million, compared with $28.88 million in the previous year.
For full‑year 2027, Kestra Medical raised its revenue guidance to $141 million, up from $137 million, reflecting a 48% increase from $95.1 million in 2026.
As of July 31, 2026, cash, cash equivalents and investments amounted to $244.7 million.
KMTS has traded in a range of $17.34 to $30.00 over the past year, closing at $24.06, a 5.30% increase on Monday.
In after‑hours trading, KMTS slipped 11.72% to $21.24.
